ZNF180

Across TCGA pan-cancer cohorts, ZNF180 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF180 data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNF180 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF180 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

LUAD, HNSC, and GBM are the cancer types where ZNF180 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.309	1.000	.022	7	view →
HNSC	DFS	Median	II,III,IV	0.826	0.308	.017	6	view →
GBM	OS	Quartile	All	0.756	0.460	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZNF180–LUAD (DFS)

Open the LUAD breakdown →